Abstract. Bone marrow mesenchymal stem cells (BMSCs) have the potential to transdifferentiate into cardiomyocyte-like cells (CLCs) if an appropriate cardiac environment is provided. Insulin-like growth factor-1 (IGF-1) plays an important role in the cell migration, survival and differentiation of BMSCs. However, the effect of IGF-1 on the cellular differentiation remains unclear. In the present study, BMSCs were isolated from rat femurs and tibias and the cells were purified at passage 6 (P6). IGF-1 and IGF-1 receptor (IGF-1R) kinase inhibitor I-OMe AG538 were added to detect if IGF-1 could induce BMSCs to transdifferentiate into CLCs and if I-OMe AG538 could inhibit IGF-1-mediated receptor activation and downstream signaling. Immunostaining demonstrated that all P6 BMSCs express CD29 and CD44 but not CD45. BMSCs induced by 15 ng/ml IGF-1 revealed positivity for cardiac troponin-T and cardiac troponin-I. The optimal induction time was 14 days but the expression of these proteins were incompletely inhibited by 300 nmol/l I-OMe AG538 and completely inhibited by 10 µmol/l I-OMe AG538. Western blotting showed that the level of IGF-1R autophosphorylation and the expression of cTnT and cTnI were higher when BMSCs were induced for 14 days. I-OMe AG538 selectively inhibited IGF-1-mediated growth and signal transduction and the inhibitory effect of I-OMe AG538 were not reverted in the presence of exogenous IGF-1. In addition, when a time course analysis of the effects of I-OMe AG538 on mitogen-activated protein kinase kinase and phosphatidylinositol 3-kinase signaling were done, we observed a transient inhibitory effect on Erk1/2 and Akt phosphorylation, in keeping with the inhibitory effects on cell growth. Taken together, these data indicate that I-OMe AG538 could inhibit IGF-1-induced CLCs in BMSCs and this effect is time-and concentration-dependent.
Introduction
Bone marrow mesenchymal stem cells (BMSCs) have the potential to transdifferentiate into cardiomyocyte-like cells (CLCs) in the heart and appear as functional phenotypes of myocardial cells (1) (2) (3) . It has been of great interest in treatment of myocardial infarction to use stem cells to prevent deterioration of heart failure and even to repair the damaged myocardium. It has been reported that growth factors added to the local microenvironment can improve the survival rate and functioning of the transplanted cells (4, 5) .
Insulin-like growth factor-1 (IGF-1) is a potent mitogen that has been proposed to play an important role in the regulation of cell proliferation, apoptosis, and tumorigenicity (6) (7) (8) . The IGF-1 receptor (IGF-1R) and the insulin receptor are structurally highly related glycoproteins. Both these receptors possess two extracellular α-subunits, which bind the ligand and two β-subunits. The receptors also span the membrane and possess the intracellular autophosphorylation sites. IGF-1 is involved in normal cell proliferation and has been implicated in oncogenesis. The IGF-1 ligand, its receptor, the IGF-1 binding proteins, and the specific proteolytic enzymes which degrade these proteins constitute an important regulatory system which plays a pivotal role in normal and neoplastic cell growth (9) . It has been reported that IGF-1 promotes migration of endothelial cells and cardiac resident progenitor cells (10-13). Li et al (4) also found that IGF-1 can simulate transdifferentiation of BMSCs into the cardiac phenotype and enhance the expression of GATA-4, but the mechanism is not clear.
In the present study, BMSCs were isolated from rat femurs and tibias and the cells were purified at passage 6 (P6). IGF-1 and IGF-1R kinase inhibitor I-OMe AG538 were added to detect if IGF-1 could induce BMSCs to transdifferentiate into CLCs and if I-OMe AG538 could inhibit IGF-1-mediated receptor activation and downstream signaling. Our study shows that I-OMe AG 538 could inhibit IGF-1-induced CLCs in BMSCs.
Materials and methods
Isolation and culture of BMSCs. BMSCs were isolated according to the method described by Panepucci et al (14) . In brief, femurs and tibias from SD rats (male, weighing 150±5 g)
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were removed. Muscle and extraosteal tissue were trimmed under sterilized conditions. Bone marrow cells were flushed and were transferred into culture flasks in 5% CO 2 incubator at 37˚C. The culture medium contained 10% fetal calf serum (FCS), (HyClone, Tauranga, New Zealand) and DMEM/F12 (Gibco, Grand Island, NY, USA) containing 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Sigma-Aldrich, St. Louis, MO, USA). Three days later, BMSCs adhered to the bottom of culture plates, and the hematopoietic cells remained suspended in the medium. Fresh medium was changed every 3 days. The sub-confluent cells in the seed cultures were removed from the flasks by 0.25 trypsin (Sigma-Aldrich) treatment 7 days after the initial plating. They were labeled as P1 and continued to culture until P6.
Drugs. I-OMe AG538 was purchased from Sigma-Aldrich. In the second experiment, to evaluate the ability of IGF-1 induced BMSCs to transdifferentiate into CLCs, 15 ng/ml IGF-1 group and control group containing 10% FCS were used in induction of BMSCs. These cells were observed for morphological changes under an inverted microscope (BX-42; Olympus, Tokyo, Japan). The expression of troponin-T and troponin-I was detected by immunocytochemistry.
In the third experiment, to evaluate the ability of IGF-1 to induce cell recovery from the cytotoxic effects of I-OMe AG538, 2x10 4 /ml cells were plated into 35 mm culture dish in DMEM/F12 plus 10% FCS. After 24 h, 15 ng/ml IGF-1 was added to the medium and 300 nmol/l, replaced by DMEM/F12 plus 10% FBS or the compound (300 nmol/l) every 6 h ≤3 days. After 72 h of treatment, the identification of BMSCs by immunocytochemical stain was performed as previously described. The primary antibody was rat monoclonal troponin-T antibody (dilution, 1:500; cat. no. ab50576) and rat polyclonal troponin-I antibody (dilution, 1:500; cat. no. ab47003) (both from Abcam, Cambridge, UK). PBS was used in the control group.
Western blotting. Constitutive activation of IGF-1R was evaluated on a panel of BMSCs. To evaluate the ability of IGF-1 to induce cell recovery from the cytotoxic effects of I-OMe AG538 toward IGF-1R kinase and signaling, starved BMSCs were treated with doses of 300 nmol/l (corresponding to IC 50 value) I-OMe AG538 for 3 h followed by stimulation with IGF-1 (Peprotech, Inc., Rocky Hill, NJ, USA) for 5 to 30 min. In a second experiment, I-OMe AG538 inhibitory effects were followed on IGF-1R-related signaling pathways by exposing BMSCs to 300 nmol/l compound for 1 to 48 h in standard medium. To determine phosphorylation status of Erk1/2 and Akt, two downstream mediators of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways, cell lysates were prepared with a buffer containing 50 mmol/l MOPS, 320 mmol/l Sucrose, 100 mmol/l Kcl, 0.5 mmol/l MgCl 2 , 1 mmol/l DTT, 50 mmol/l NaF, 20 mmol/l NaPPi, 20 mmol/l β-glycerophosphate, 1 mmol/l Na 3 VO 4 , 1 mmol/l EDTA, and protease inhibitors (0.5 mmol/l phenylmethylsulfonyl fluoride, 0.5 mmol/l leupeptin).
In the third experiment, to evaluate the ability of IGF-1 to induce BMSCs to transdifferentiate into CLCs which had been added with 300 nmol/l I-OMe AG538, we collected BMSCs which were induced by IGF-1 for 3 days. The experiment followed as above. Protein concentration was determined by BCA protein assay (Thermo Labsystems, Santa Rosa, CA, USA) and equivalent amounts of total cell lysate (50 µg) were separated by 4 or 10% SDS-PAGE under denaturing conditions and transferred onto nitrocellulose membrane. Membranes were incubated with 5% bovine serum albumin confining liquid overnight, then with primary antibodies. Rabbit monoclonal phospho-IGF-1R antibody (dilution, 1:1,000; cat. no. 3918S); rabbit monoclonal IGF-1R antibody (dilution: 1:1,000; cat. no. 14534S); rabbit monoclonal phospho-Akt antibody (dilution, 1:1,000; cat. no. 12178S); rabbit monoclonal Akt antibody (dilution, 1:1,000; cat. no. 11848) and rabbit monoclonal Erk1/2 antibody (dilution, 1:1,000; cat. no. 4348S) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA). Then the goat anti-rabbit secondary antibody (dilution, 1:2,000; cat. no. ab6721; Abcam, Cambridge, MA, USA) was added. In all experiments, final concentration of DMSO in the medium was <0.001%, and in the present study, it had no effect on cell growth inhibition. This method was described by Scotlandi et al (15) .
Results

Morphological changes of BMSCs in vitro.
BMSCs were successfully expanded and used for subsequent experiments. At first, single cells of spindle morphology were observed 3-4 days after the initial seeding. The morphologic appearance of the cell population was fairly homogeneous (Fig. 1A) . About 1 week later, most cells appeared as fibroblasts with spindle or shuttle shape. The colonies continuously grew, reaching 80-90% confluence in 2 weeks. However, there were some blood cells in the view. When they were labeled at P6, cells were already purified and there were no blood cells in the view and the confluence was whirlpool-like (Fig. 1B) .
The identification of BMSCs. All P6 BMSCs express CD29 (Fig. 2C) and CD44 (Fig. 2D) , but there was no staining for CD45 (Fig. 2B) . This demonstrated that these cells were BMSCs but haemopoietic stem cells. We confirmed that the method to isolate BMSCs was feasible and highly purified cells could be obtained with this method.
The ability of IGF-1 to induce BMSCs to transdifferentiate into CLCs.
After BMSCs were exposed to 15 ng/ml of IGF-1 for 21 days, the morphology of BMSCs did not change. The expression of troponin-T and troponin-I were significantly higher in the 14-day group than control group (Fig. 3) and the levels of pIGF-1R were higher in the 14-day group than other groups (Fig. 4) . Fig. 5 demonstrates that similar inhibitory effects were obtained in BMSCs with various concentrations using I-OMe AG538. Growth inhibitory activity of the compound was maintained for ≥72 h after its removal (50% of growth inhibition with the dose of 331.7±2.3 nmol/l; P<0.05) (Fig. 5) . To confirm the inhibitory activity of I-OMe AG538 toward IGF-1R kinase and signaling, starved BMSCs were treated with doses of 300 nmol/l for 3 h followed by stimulation with IGF-1 for 5 to 30 min. Fig. 6 shows that both IGF-1R autophosphorylation and the two major IGF-1R-related intracellular signaling pathways, MAPK and PI3K pathways, were inhibited by I-OMe AG538.
I-OMe AG538 selectively inhibits IGF-1-mediated growth and signaling.
I-OMe AG538 blocks the differentiation into CLCs of BMSCs induced by IGF-1.
To confirm the inhibitory activity of I-OMe AG538 and whether it blocks the differentiation of BMSCs into CLCs induced by IGF-1, BMSCs were treated with 15 ng/ml IGF-1 and 300 nmol/l or 10 µmol/l I-OMe AG538. Fig. 7 shows that the expression of troponin-T and troponin-I were inhibited by 300 nmol/l I-OMe AG538.
In vitro activity of I-OMe AG538 on BMSCs. A time course evaluation of inhibitory effects of 300 nmol/l Figure 6 . Effects of I-OMe AG538 on IGF-1-mediated receptor activation and cell growth. Starved cells were treated with I-OMe AG538 for 3 h followed by stimulation with 15 ng/ml IGF-1 for 5 to 30 min (5 min for evaluation of MAPK family members Erk1/2 and IGF-1R phosphorylation and 30 min for PI3K mediator Akt activation). IGF-1R was immunoprecipitated and blotted with an anti-phospho-tyrosine antibody to visualize its level of tyrosine phosphorylation. Erk1/2 and Akt phosphorylation was immunodetected with specific antibodies on whole cell lysates. Anti-Akt, anti-Erk1/2 or anti-IGF-1R antibodies were used to detect total proteins as controls (n=3). IGF-1R, insulin-like growth factor-1 receptor. I-OMe AG538 on MAPK and PI3K signaling pathways in standard medium, however, revealed transient effects on MAPK and PI3K pathway, particularly for the dose of 300 nmol/l (Fig. 8) .
Discussion
The traditional belief has been that the cardiac muscle is a terminally differentiated tissue and can only be replaced by scar tissue after a myocardial infarction. To maintain cardiac pumping following an infarction, remodeling of the degenerative left ventricle occurs, causing a decrease in cardiac function and leading to heart failure (4). BMSCs have been considered to be one of the potential cell sources for cellular cardiomyoplasty due to their multipotency and immunomodulatory properties (2, 16, 17) . Although there is great enthusiasm for repairing the heart by using cell therapy, simple cell implantation cannot reinstate cell transdifferentiation or reverse apoptosis. Furthermore, experimental data indicate that only a small number of cells can be implanted in the host tissue with normal function. Therefore, attempts at using various approaches to enhance the effectiveness of cell therapy have become a challenge (16) . However, utilizing growth factors in a local tissue environment to increase the survival of transplanted cells may be practical. IGF-1 has been considered as a potent growth hormone capable of inducing cell proliferation, limiting apoptotic cell death, and attenuating maladaptive extracellular matrix remodeling in the failing heart (17, 18) . IGF-1 can promote angiogenesis in the infarcted myocardium, reduce the degree of myocardial necrosis, maintain the myocardial structure, stimulate proliferation of cardiac fibroblast and inhibit matrix degradation. Thus, IGF-1 can prevent ventricular dilatation and reduce load capacity of the heart (19) (20) (21) (23) found that insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. IGF-1R is the most important individual component of the IGF axis that includes the ligands IGF-1 and IGF-2, six high-affinity IGF-binding proteins, several proteases, and three receptors (24) . In general, the activation of IGF/IGF-1R signaling promotes proliferative and survival mechanisms that can be usefully exploited by many cells (25) .
In the present study, in order to determine whether 15 ng/ml IGF-1 could induce BMSCs to transdifferentiate into CLCs and have a heart cell phenotype, cells were treated with antibodies against proteins expressed in cardiac cells, including troponin-T and troponin-I. After BMSCs were exposed to 15 ng/ml IGF-1 for 21 days, the morphology of BMSCs did not change. Immunocytochemistry analysis and western blotting all showed that the expression of troponin-T and troponin-I were significantly higher in the 14 day group than control group and the level of pIGF-1R was also higher in 14 day group than the control group. These results suggested that IGF-1 could induce BMSCs to transdifferentiate into CLCs and have a heart cell phenotype.
IGF-1R kinase inhibitor I-OMe AG538 were added to detect if I-OMe AG538 could inhibit IGF-1-mediated receptor activation and downstream signaling. Our data showed that I-OMe AG538 was found to fulfill the key features expected from an IGF-1R inhibitor. It selectively inhibits IGF-1-mediated growth and signal transduction in BMSCs. Of note, the inhibitory effects of I-OMe AG538 were not completely reverted in the presence of 15 ng/ml IGF-1. BMSCs are sensitive to I-OMe AG538 and therefore, when a time course analysis of the effects of I-OMe AG538 on MAPK and PI3K signaling was done, we observed a transient inhibitory effect on Erk1/2 and Akt phosphorylation, which is in keeping with the inhibitory effects on cell growth.
In conclusion, BMSCs can transdifferentiate into CLCs and obtain the myocardial cell phenotype in the presence of IGF-1 (13) . In addition, the induction effects of IGF-1 can be blocked by the inhibitor of IGF-1R kinase and be timedependent. However, as we know, PI3K/Akt is the dominant signaling pathway underlying IGF-1 enhanced cell survival and migration (22, 26) , and the Ras/Raf/MEK/ERK MAPK pathway regulates the expression of a large number of proteins involved in the control of cell proliferation, differentiation, and apoptosis (27, 28) . Therefore, if the effect that IGF-1 induces BMSCs to transdifferentiate into CLCs is through the MAPK/ERK pathway, then that needs to be further studied.
